{"schema_version":"secwatch.filing_event.v1","accession":"0000926617-23-000072","form_type":"8-K/A","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.062755+00:00","generated_at":"2026-06-11T13:41:33.278965+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aspira Women's Health Q2 revenue $2.5M, up 23% YoY; cash burn down 46%","bullets":["Q2 2023 revenue $2.5M (+23% YoY); OvaSuite volume 6,289 (+16%); gross margin 62% vs 47% in Q2 2022.","Cash used in operations $3.4M, down 46% from $6.3M in Q2 2022; total cash $4.5M at June 30.","Lowered H2 2023 operating cash guidance to $6–8M; received $1M debt forgiveness from Connecticut DECD.","Raised $4.3M net in July 2023 registered direct offering; total outstanding debt ~$1.6M.","Appointed Torsten Hombeck as CFO; COO/CSO Ryan Phan to depart Sept 15; new director Winfred Parnell appointed."],"urls":{"canonical":"https://secwatch.observer/filing/0000926617-23-000072","json":"https://secwatch.observer/filing/0000926617-23-000072.json","markdown":"https://secwatch.observer/filing/0000926617-23-000072.md","text":"https://secwatch.observer/filing/0000926617-23-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000072/0000926617-23-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000072/awh-20230814x8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T13:41:33.278965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24f79e412e2c7137e8f7d683bcbc6c5895241f9f","claim":"Aspira Women's Health Inc. reported second quarter ended June 30, 2023 results: revenue $2.5 million. Guidance lowered.","evidence_excerpt":"(EX-99.1) --- 2023-08-14 8K Ex 991 Exhibit 99 .1 Aspira Women’s Health ® Reports Second Quarter 2023 Financial Results  Continued growth trend with second quarter revenue of $2.5 million, an increase of 23% over the second quarter of 2022. OvaSuite volume of 6,289 units, an increase of 16% year-over-year Achieved cash used in operations of $3.4 million, a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000072/0000926617-23-000072-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$2.5 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}